The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer

Abstract

BackgroundPrognostic factors aid in the stratification and treatment of cancer. This study evaluated the prognostic significance of human epidermal growth factor receptor (HER) family members (HER1–4) expression in patients with operable pancreatic cancer.MethodsThe expression of individual HER proteins in patient tissue specimens was detected by immunohistochemistry staining. Patient follow-up time was between 1.0 and 78.1 months.ResultsPositive expression of HER1, HER2, HER3 and HER4 was detected in 41.4, 60.0, 24.3 and 65.7% of cases, respectively. Kaplan–Meier analysis revealed that HER3 positive expression was associated with decreased median survival time (12.0 vs. 25.6 months for HER3 positive and negative groups, respectively; P = 0.013). Cox’s regression confirmed that positive HER3 expression was an independent predictor of poor survival (RR = 3.684, P = 0.001). In contrast, HER4 negative patients had a significantly decreased median survival time when compared with HER4 positive patients (11.4 vs. 25.6 months, respectively; P = 0.027). However, HER4 was not an independent predictor of survival. No significant association between HER1 or HER2 expression and survival was observed (P = 0.626 & P = 0.859, respectively).ConclusionsHER3 is an independent prognostic marker for patients with operable pancreatic cancer. HER4 may also be of potential prognostic value in this disease and deserves further attention.

Transient receptor potential vanilloid 1 promotes EGFR ubiquitination and modulates EGFR/MAPK signalling in pancreatic cancer cells

“…In some clinical samples, EGFR showed a significantly higher expression in pancreatic adenocarcinoma compared with normal pancreatic tissue and were confirmed by TASC scoring as a promising imaging target. In pancreatic adenocarcinoma, EGFR expression varies from 25% to 69% in different studies and has been associated with advanced stage, metastastic disease, poor differentiation, and survival . EGFR signalling is also one of the main reasons behind the early invasion and metastasis of pancreatic cancer, which leads to the poor prognosis of this disease …”

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer

“…This leads to an auto and/or trans-phosphorylation of C-terminal region of the intracellular tyrosine kinase domain leading to the activation of various downstream signaling pathways such as PI3K-AKT, RAS/RAF/MAPK, JAK-STAT and PLC-γ1 that regulates proliferation, metabolism, angiogenesis, cell progression and survival (7)(8)(9). In some studies, aberrant expression and activation of HER-mediated signaling has been associated with tumor aggressiveness and a poorer prognosis in patients with pancreatic cancer (7,(10)(11)(12)(13). However, of the HER inhibitors, only the reversible EGFR-specific erlotinib has been approved by the US FDA for the treatment of locally advanced, unresectable or metastatic pancreatic cancer when used in combination with gemcitabine (14).…”

State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?

“…Poteet et al have investigated a combination of EGFR inhibitors (cetuximab, gefitinib) with trametinib (MEK-inhibitor) and concluded that this combination could present a novel effective treatment for PDAC (16). Moreover, the authors found possible predictors of sensitivity to EGFR-inhibitors (mesothelin and TGF-α) (17).…”